Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.
Around 20% of meningiomas histologically benign may be clinically aggressive and recur.This strongly affects management of meningioma patients.There is a need to evaluate the potential aggressiveness of an individual meningioma.Additional criteria for better classification of meningiomas will improve clinical decisions as well as patient follow up